Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapeutics, is broadening its plasma collection infrastructure with the launch of a new center in San Antonio, Texas. The 11,100-square-foot facility is designed to support up to 50 donor beds and is projected to collect approximately 50,000 liters of plasma annually, marking a significant step in the company's strategic expansion.
The new plasma collection center will focus on gathering hyper-immune plasma, a critical resource containing high-concentration antibodies used in treating and preventing various infections and diseases. These specialized plasma products play a crucial role in medical treatments, including protecting organ transplant recipients, treating hepatitis B, and preventing rabies in individuals exposed to potentially rabid animals.
Pending approval from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), expected within nine to twelve months, the facility represents Kamada's commitment to reducing dependency on third-party plasma suppliers. By developing its own collection capabilities, the company anticipates improved cost management and potentially becoming a plasma supplier for other industry players.
Kamada's CEO, Amir London, emphasized the strategic importance of the new center, noting that it will expand the company's collection capacity for specialty plasma types such as Anti-Rabies and Anti-D. Once fully operational, the facility is expected to generate between $8 million and $10 million in annual revenue through the sale of normal source plasma to other medical manufacturers.
This expansion builds upon Kamada's existing plasma collection infrastructure, which includes facilities in Beaumont and Houston, Texas. The company has already received FDA approval for six plasma-derived therapeutics targeting rare and underserved medical conditions, positioning itself as a potential leader in the specialty plasma therapeutics market.
The new San Antonio center underscores Kamada's broader strategic vision of enhancing its plasma collection and therapeutic development capabilities. By investing in specialized plasma collection, the company aims to improve its ability to develop critical medical treatments and potentially reduce overall production costs.
